Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg

Neurology

Volumn 82, Issue 10, 2014, Pages 879-886

  Querol, Luis ^a,b   Nogales Gadea, Gisela ^a,b   Rojas Garcia, Ricardo ^a,b   Diaz Manera, Jordi ^a,b   Pardo, Julio ^c   Ortega Moreno, Angel ^d   Sedano, Maria Jose ^b,e   Gallardo, Eduard ^a,b   Berciano, Jose ^b,e   Blesa, Rafael ^a   Dalmau, Josep ^f,g   Illa, Isabel ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROFASCIN 155 ANTIBODY; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ADULT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ATAXIA; BASAL GANGLION; BRAIN STEM; CEREBELLUM; CLINICAL FEATURE; COMPOUND MOTOR ACTION POTENTIAL; CONTROLLED STUDY; DENERVATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LATENT PERIOD; LIMITED MOBILITY; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MOTOR NERVE CONDUCTION; NEUROGRAPHY; NEUROIMAGING; NEUROPIL; NONHUMAN; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RAT; RELAPSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TREMOR; WEAKNESS;

ADULT; ANIMALS; AUTOANTIBODIES; CELL ADHESION MOLECULES; DRUG RESISTANCE; FEMALE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PHENOTYPE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RATS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREMOR;

EID: 84896262532     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000205     Document Type: Article

References (32)

1. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
2. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010;15:1-9.
3. Brannagan TH III. Current diagnosis of CIDP: the need for biomarkers. J Peripher Nerv Syst 2011;16(suppl 1):3-13.
4. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009;(1):CD001797.
5. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;(3): CD003906.
6. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980;37:637-640.
7. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA 2009;106:4788-4792.
8. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006;11:30-46.
9. Doppler K, Werner C, Sommer C. Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies. J Peripher Nerv Syst 2013;18:168-176.
10. Cifuentes-Diaz C, Dubourg O, Irinopoulou T, et al. Nodes of Ranvier and paranodes in chronic acquired neuropathies. PLoS One 2011;6:e14533.
11. Pollard JD, Armati PJ. CIDP: the relevance of recent advances in Schwann cell/axonal neurobiology. J Peripher Nerv Syst 2011;16:15-23.
12. Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barré syndrome. J Peripher Nerv Syst 2012;17:62-71.
13. Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 2012;79:2241-2248.
14. Pruss H, Schwab JM, Derst C, Gortzen A, Veh RW. Neurofascin as target of autoantibodies in Guillain-Barré syndrome. Brain 2011;134:e173.
15. Mathey E, Yan W, Yuki N, Ji Q, Yiannikas C, Pollard J. Antineurofascin antibodies are present in patients with peripheral demyelinating neuropathies and mediate changes in nerve conduction in animals. J Peripher Nerv Syst 2010; 15:288-289.
16. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013;73:370-380.
17. Labasque M, Devaux JJ, Leveque C, Faivre-Sarrailh C. Fibronectin type III-like domains of neurofascin-186 protein mediate gliomedin binding and its clustering at the developing nodes of Ranvier. J Biol Chem 2011;286: 42426-42434.
18. Sherman DL, Tait S, Melrose S, et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 2005;48:737-742.
19. Faivre-Sarrailh C, Banerjee S, Li J, Hortsch M, Laval M, Bhat MA. Drosophila contactin, a homolog of vertebrate contactin, is required for septate junction organization and paracellular barrier function. Development 2004;131:4931-4942.
20. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204:2363-2372.
21. Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013;81:714-722.
22. Querol L, Rojas-Garcia R, Casasnovas C, et al. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve 2013;48:870-876.
23. Thaxton C, Pillai AM, Pribisko AL, et al. In vivo deletion of immunoglobulin domains 5 and 6 in neurofascin (Nfasc) reveals domain-specific requirements in myelinated axons. J Neurosci 2010;30:4868-4876.
24. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-Nmethyl- D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.
25. Pillai AM, Thaxton C, Pribisko AL, Cheng JG, Dupree JL, Bhat MA. Spatiotemporal ablation of myelinating glia-specific neurofascin (Nfasc NF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains. J Neurosci Res 2009;87:1773-1793.
26. Deuschl G, Bergman H. Pathophysiology of nonparkinsonian tremors. Mov Disord 2002;17(suppl 3):S41-S48.
27. Saifee TA, Schwingenschuh P, Reilly MM, et al. Tremor in inflammatory neuropathies. J Neurol Neurosurg Psychiatry 2013;84:1282-1287.
28. Schwingenschuh P, Saifee TA, Katschnig-Winter P, et al. Cerebellar learning distinguishes inflammatory neuropathy with and without tremor. Neurology 2013; 80:1867-1873.
29. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011;23:119-124.
30. Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 2009;7:337-342.
31. Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011;82:87-91.
32. Tackenberg B, Nimmerjahn F, Lunemann JD. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 2010;30(suppl 1):S65-S69.